Eating Disorders & Weight Management News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, the sector…#goldmansachs #novonordisk #nvo #novonordisks #amycretin #novo #wegovy #amgen #amgn #easily (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2024 Category: Consumer Health News Source Type: news

Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Shares of Novo Nordisk (NYSE: NVO) rose to a new all-time high on Thursday, March 7. The market was responding to encouraging results from a clinical trial with an experimental weight-management drug called amycretin. Amycretin is an orally available treatment candidate, which could give it a big…#novonordisk #nvo #amycretin #wegovyand #elililly #lly #glp1 #wegovyandozempic #amylin #cagrisema (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2024 Category: Consumer Health News Source Type: news

Urgent warning over 'incredibly harmful' starvemaxxing TikTok trend that charities fear could cause eating disorders
'Starvemaxxing' videos on TikTok have amassed 8million views. Eating disorder charity Beat fears the trend could be 'incredibly harmful' if someone is struggling with an eating disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - March 10, 2024 Category: Consumer Health News Source Type: news

The Best Stocks to Invest $50,000 in Right Now
If you're planning to invest a considerable sum in the stock market, take a look at the following businesses first. These elite enterprises are proven wealth builders, and their stocks are all smart buys today. If you're searching for a low-risk way to profit from the growth of artificial…#msft #openai #excel #obese #elililly #lly #zepbound #yahoo #costcowholesale #cost (Source: Reuters: Health)
Source: Reuters: Health - March 10, 2024 Category: Consumer Health News Source Type: news

Eli Lilly's campaign seeks to resolve weight-loss drug misconceptions
Pharmaceutical giant Eli Lilly and Company is trying to clear up misconceptions about obesity care as it increases investment in its highly popular weight-loss drugs. With the latest phase of Lilly's "Get Better" campaign, the company aims to focus the importance of obesity treatment as a disease,…#elilillyandcompany #lilly #elonmusk #fda #bignight #shame #novo #wegovyandozempic #elililly #lillydirect (Source: Reuters: Health)
Source: Reuters: Health - March 9, 2024 Category: Consumer Health News Source Type: news

The Top 3 Pharma Stocks to Buy in March2024
Discover the top three pharma stocks ready to soar in 2024's booming market Investors’ eyes are closely following the massive rally in pharmaceutical stocks amid the red-hot anti-obesity market. In 2024, the projected revenue for the pharma market is estimated to reach $1.15 trillion. And,…#goldmansachsresearch #elililly #lly #eps #yoy #mounjaro #elilillys #bankofamerica #denmark #novonordisk (Source: Reuters: Health)
Source: Reuters: Health - March 9, 2024 Category: Consumer Health News Source Type: news

Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients
The popular weight-loss drug Wegovy can now be used to reduce the risk of stroke, heart attacks and other serious heart problems in patients who are overweight or who have obesity (Source: ABC News: Health)
Source: ABC News: Health - March 8, 2024 Category: Consumer Health News Tags: Health Source Type: news

Wegovy Is Good for More Than Just Weight Loss
The obesity drug Wegovy can now claim to lower the risk of heart attack, stroke, and other cardiovascular issues in people who are overweight or who have obesity, and also have cardiovascular disease. It’s the first weight-loss drug to carry an indication for heart benefits. The U.S. Food and Drug Administration (FDA) approved the addition to the label on March 8 based on a study from Wegovy’s manufacturer, Novo Nordisk, showing that the drug lowered the risk of heart attack, stroke, or dying of heart-related issues in this population by 20% compared to people receiving placebo. [time-brightcove not-tgx=...
Source: TIME: Health - March 8, 2024 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news

FDA Approves Wegovy to Lower Risk for CVD Events in Patients With Obesity
FRIDAY, March 8, 2024 -- The U.S. Food and Drug Administration has approved Wegovy (semaglutide) for the prevention of myocardial infarction, stroke, and cardiovascular death in patients with obesity or overweight. In one multinational study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2024 Category: Pharmaceuticals Source Type: news

FDA approves Wegovy weight-loss shot for heart disease patients - including those who are not obese
The FDA approved the medication for this use in non-diabetic patients who had heart disease today, following clinical trials showing it slashed the risk of the complications by up to 28 percent. (Source: the Mail online | Health)
Source: the Mail online | Health - March 8, 2024 Category: Consumer Health News Source Type: news

Wegovy Approved in the US for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease
Bagsværd, Denmark, 8 March 2024– Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 8, 2024 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
The FDA approved a new use for a drug to reduce the risk of cardiovascular disease, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Options Medical Weight Loss Announces Tips to Commemorate Obesity Care Week
Premier medical weight loss clinic offers the chance to win a complimentary* program. COLUMBUS, Ohio, March 8, 2024 /PRNewswire-PRWeb/ -- Options Medical Weight Loss is honoring Obesity Care Week throughout the month of March with education and weight loss program giveaways. As part of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 8, 2024 Category: Pharmaceuticals Source Type: news

Wegovy Approved for Major Heart Disease Prevention
(MedPage Today) -- The FDA approved semaglutide (Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight, the agency announced on Friday. A GLP-1 receptor... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 8, 2024 Category: Cardiology Source Type: news

Look to Your Parents for Your Odds of Obesity: Study
FRIDAY, March 8, 2024 -- Folks worried about becoming flabby in middle age should check out what their parents looked like when they were that age, a new study says.People are six times more likely to become obese in middle age if both their... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 8, 2024 Category: General Medicine Source Type: news